← Eichor
Condition: Bevacizumab Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Bevacizumab

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

FSRT Combines With Bevacizumab for Multiple Brain Metastases in Lung Adenocarcinoma
Phase 3 · 1 location(s) · Sun Yat-Sen University Cancer Center · NCT07058428Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk R
Phase 2 · 4 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT07239245Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Pr
Phase 1/Phase 2 · 4 location(s) · Imunon · NCT05739981AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer
Phase 3 · 2 location(s) · Akeso · NCT06951503FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-S
Phase 2 · 13 location(s) · Oncolytics Biotech · NCT07446322Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant
Phase 4 · 1 location(s) · Icahn School of Medicine at Mount Sinai · NCT07059494RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study
Phase 2 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT07065435Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared
Phase 3 · 1 location(s) · Northwell Health · NCT05271240Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian Cancer
Phase 2 · 1 location(s) · Qilu Hospital of Shandong University · NCT06735326Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Phase 3 · 604 location(s) · National Cancer Institute (NCI) · NCT04181060Esophageal Varices Prophylaxis in Hepatocellular Carcinoma Treated With Atezolizumab and Bevacizumab
NA · 1 location(s) · Tanta University · NCT06961526Short-course Radiotherapy Followed by Sequential Chemotherapy With or Without PD-1 Monoclonal Antibody and Bevacizumab a
Phase 2 · 1 location(s) · Dechang Diao · NCT07005570Liposomal Irinotecan (II) Fractionated Dosing Combined With 5-FU/LV (FOLFIRInali-3) and Bevacizumab in Second-line Treat
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07047560Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast Cancer
Phase 2 · 14 location(s) · Yukinori Ozaki · NCT06976944Intrathecal Injection Pemetrexed And Bevacizumab in Patients With Leptomeningeal Metastases in NSCLC
Phase 1 · 1 location(s) · Shanghai Chest Hospital · NCT06663306Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma
Phase N/A · 1 location(s) · Sun Yat-sen University · NCT06323382Study to Evaluate the Efficacy and Safety of Atezolizumab and Bevacizumab as Neoadjuvant Plus Adjuvant Treatment in HCC
Phase 2 · 12 location(s) · Fundacion Clinic per a la Recerca Biomédica · NCT07018947A Single-center, Phase II Study on Efficacy & Safety of SCRT+CAPOX+Serplulimab+Bevacizumab for MSS Rectal Cancer
Phase 2 · 1 location(s) · First Affiliated Hospital of Wenzhou Medical University · NCT07347951Neoadjuvant Chemotherapy Combined With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07)
Phase 2 · 2 location(s) · First Affiliated Hospital of Zhejiang University · NCT07351487A Study of SHR-2524 Plus Bevacizumab in the First-line Treatment of Advanced Hepatocellular Carcinoma
Phase 1 · 2 location(s) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. · NCT07478302Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebreli
Phase 2 · 1 location(s) · The Fourth Affiliated Hospital of Zhejiang University School · NCT06282445Bevacizumab in Combination With Sintilimab Versus Transcatheter Arterial Chemoembolization for the Treatment of Intermed
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT06090656Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Beva
Phase 3 · 32 location(s) · Genelux Corporation · NCT05281471Study of SHR-A1811 Combined With Pyrotinib and Bevacizumab in Advanced Breast Cancer With Brain Metastasis
Phase 1/Phase 2 · 1 location(s) · Fudan University · NCT06718933Efficacy of the Combination of Trimipramine and Atezolizumab With Bevacizumab in Patients With Recurrent Glioblastoma: a
Phase 2 · 7 location(s) · Centre Hospitalier Universitaire Vaudois · NCT07263438Spectroscopic MRI, Proton Therapy, and Avastin for Recurrent Glioblastoma
NA · 1 location(s) · University of Miami · NCT05284643Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treat
Phase 2 · 14 location(s) · Delcath Systems Inc. · NCT06607458XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT05970302Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinom
Phase 2 · 1 location(s) · Suzhou Zelgen Biopharmaceuticals Co.,Ltd · NCT06558227Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocell
Phase 2 · 1 location(s) · The First Affiliated Hospital of Xiamen University · NCT05970666
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.